StrongDecrease
Body weight
Tirzepatide → Body weight
Tirzepatide → Body weight
Evidence profile
StrongDecreaseWeight & Anthropometrics
Unlock full evidence details
Research Summary
Analyzed using Evidence Intelligence™
Tirzepatide improves glycemic control and weight loss in type 2 diabetes
Key finding
LS mean reductions in HbA1c were significantly greater in patients with a higher baseline HbA1c.
The study analyzed the efficacy of tirzepatide in patients with type 2 diabetes, showing significant reductions in HbA1c, body weight, and fasting serum glucose.
Evidence strength
Moderate confidence
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
High bias
Last updated July 4, 2026Quick read
Study at a glance
The essential study design details in one scan.
Population
Young Adult (19–39), Middle Aged (40-64), Male, Female, Asia-Pacific (APAC), with T2 Diabetes
Intervention
Tirzepatide 5 mg
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Primary outcome
HbA1c
Comparator
Insulin Glargine
Plain-language summary
What this paper says
A plain-language read of the study's main message and where it applies.
Study focus
The study analyzed the efficacy of tirzepatide in patients with type 2 diabetes, showing significant reductions in HbA1c, body weight, and fasting serum glucose.
Clinical relevance
These findings are clinically significant as they suggest that tirzepatide may offer a more effective treatment alternative for managing type 2 diabetes, potentially leading to better patient outcomes. With obesity being a common issue among diabetes patients, the weight loss associated with tirzepatide could also help improve overall health and reduce diabetes-related complications.
Keep in mind
Effectiveness of tirzepatide doses was unclear for gastrointestinal adverse events. Hypoglycemia outcomes were evaluated but not specified in results. Study results may not be generalizable to all populations with type 2 diabetes.
Published in
Journal Reference
Publication details and source links for this paper.
Yan B, Song L, Jiani T, Liying D, Linong J. Post Hoc Analysis of SURPASS-AP-Combo: Efficacy of Tirzepatide in Patients with Type 2 Diabetes. Diabetes Therapy. 2024;15(5):1125-1137. doi:10.1007/s13300-024-01561-2
Save this study and add notes to your research library.
Main Effects
All tirzepatide doses reduced HbA1c by -2.52% (p=0.001).
All tirzepatide doses reduced body weight by -5.83 kg (p=0.01).
All tirzepatide doses reduced fasting serum glucose by -15 mg/dL (p=0.001).
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Tirzepatide and Body weight, Daily glucose average, Gastrointestinal disorders incidence, and 3 more.
This study contributes evidence to
Primary intervention
Tirzepatide
Primary outcomes
- Body weight
- Daily glucose average
- Gastrointestinal disorders incidence
Evidence topics
Primary intervention
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
6
Evidence pairs
6
Relationships
3
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
3
Related topics
6
Evidence pairs
291
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 6 evidence relationships
- Includes primary outcome data
- Linked to 3 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Core evidence
Study findings
The primary outcomes reported in this study.
StrongDecrease
Daily glucose average
Tirzepatide → Daily glucose average
Tirzepatide → Daily glucose average
Evidence profile
StrongDecreaseGlycemic Control
Unlock full evidence details
NoneNo Change
Gastrointestinal disorders incidence
Tirzepatide → Gastrointestinal disorders incidence
Tirzepatide → Gastrointestinal disorders incidence
Evidence profile
NoneNo ChangeSafety
Unlock full evidence details
StrongDecrease
HbA1c
Tirzepatide → HbA1c
Tirzepatide → HbA1c
Evidence profile
StrongDecreaseGlycemic Control
Unlock full evidence details
NoneNo Change
Hypoglycemia events
Tirzepatide → Hypoglycemia events
Tirzepatide → Hypoglycemia events
Evidence profile
NoneNo ChangeSafety
Unlock full evidence details
StrongDecrease
Serum Glucose
Tirzepatide → Serum Glucose
Tirzepatide → Serum Glucose
Evidence profile
StrongDecreaseGlycemic Control
Unlock full evidence details
Unlock full evidence analysis
Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.
Evidence Suggest
- Tirzepatide significantly reduced HbA1c levels by -2.52%.
- Tirzepatide led to a weight loss of -5.83 kg.
- Fasting serum glucose decreased by -15 mg/dL with tirzepatide.
Who this applies to
- Adults diagnosed with type 2 diabetes.
- Patients seeking alternatives to insulin therapy.
Keep in Mind
- Further studies are needed to evaluate long-term safety and efficacy.
- The study's population may not represent all demographics of diabetes patients.
- Gastrointestinal adverse events and hypoglycemia were not fully detailed.
Between the Lines
- Effectiveness of tirzepatide doses was unclear for gastrointestinal adverse events.
- Hypoglycemia outcomes were evaluated but not specified in results.
- Study results may not be generalizable to all populations with type 2 diabetes.
Unlock Full Analysis
Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.
Already have an account?
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and HbA1c, GLP-1 Receptor Agonists and Body Weight.
Related evidence relationships
Explore in Evidence ArchiveThis study contributes to the evidence on the following intervention-outcome relationships.
Included in these evidence collections
Curated evidence collections and hubs this study is part of.
GLP-1 Receptor Agonists Evidence Hub
All studies on GLP-1 Receptor Agonists
8 studies
intervention_hubContributes to GLP-1 Receptor Agonists evidence base.
HbA1c Evidence Hub
All studies measuring HbA1c
8 studies
outcome_hubMeasures HbA1c as a key outcome.
Body Weight Evidence Hub
All studies measuring Body Weight
7 studies
outcome_hubMeasures Body Weight as a key outcome.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in the evidence archive
Jump to pre-filtered views in the evidence archive.
All studies on Tirzepatide and HbA1c
Intervention: TirzepatideOutcome: HbA1c
8 results
All studies on Tirzepatide and Body weight
Intervention: TirzepatideOutcome: Body weight
7 results
All studies on Tirzepatide
Intervention: Tirzepatide
8 results
All studies measuring HbA1c
Outcome: HbA1c
8 results
All studies measuring Body weight
Outcome: Body weight
7 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does GLP-1 Receptor Agonists affect body weight?
Strong Evidence
GLP-1 Receptor Agonists may improve Body Weight.
ConsensusScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Strong | EvidenceScore™ 82.5 | strong positive | ConsensusScore™ Consistent | 1 study
Why this answer: This answer is based on 23 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists improve HbA1c?
Strong Evidence
GLP-1 Receptor Agonists appears to improve HbA1c.
ConsensusScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 85.1 | strong positive | ConsensusScore™ Consistent | 1 study
Why this answer: This answer is based on 24 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists affect hypoglycemia?
Strong Evidence
GLP-1 Receptor Agonists may improve Hypoglycemia.
ConsensusScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Hypoglycemia events
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on 11 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists improve fasting glucose?
Strong Evidence
GLP-1 Receptor Agonists may improve Fasting Glucose.
ConsensusScore™: Results are generally consistent across studies.
Ranked evidence signals
- 1
Serum Glucose
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on 7 supporting studies with generally consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, archive views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in archive
Open broader archive views for this relationship.
Related research
Read related research summaries.
Newer diabetes drugs show stronger weight and blood sugar benefits in prediabetesTirzepatide improves glycemic control in early-onset type 2 diabetesTirzepatide enhances insulin sensitivity in type 2 diabetesMetformin and glimepiride with basal insulin lowered HbA1c the mostSwitching to tirzepatide from dulaglutide improved HbA1c and weight across baseline characteristics
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.